Individualizing prophylaxis in hemophilia: a review
- 20 January 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 8 (2), 237-246
- https://doi.org/10.1586/17474086.2015.1002465
Abstract
Prophylaxis is considered optimal care for patients with severe hemophilia to prevent bleeding, including hemarthroses, which may cause arthropathy with chronic pain, occupational impairment and progressive loss of mobility. Questions remain regarding the optimal delivery of prophylaxis including how to individualize prophylaxis and optimize outcomes for each patient. Designing a prophylactic regimen for severe hemophilia must account for each patient's unique disease course, bleeding pattern, presence/absence of joint damage, pharmacokinetic profile, level of physical activity and adherence to treatment. Standard weight-based prophylaxis regimens and regimens optimized by bleeding phenotype (i.e., patients are 'allowed' to bleed to dose optimization) fail to prevent complications in many patients. Pharmacokinetic-guided dosing enables precise adjustment of dosing level and frequency to maintain adequate hemostatic levels and prevent bleeding. Optimal outcomes, such as reducing or eliminating hemorrhages, preventing or minimizing joint damage, and improving quality of life, can be achieved through an individualized care approach.Keywords
This publication has 59 references indexed in Scilit:
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Developing models of haemophilia careHaemophilia, 2012
- Quantifying factors for the success of stratified medicineNature Reviews Drug Discovery, 2011
- The Path to Personalized MedicineNew England Journal of Medicine, 2010
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis StudyJournal of Thrombosis and Haemostasis, 2006
- What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?Haemophilia, 2001
- Primary prophylaxis in severe haemophilia should be started at an early age but can be individualizedBritish Journal of Haematology, 1999
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992
- Haemophilia in Sweden VII. Incidence, Treatment and Prophylaxis of Arthropathy and other Musculo-Skeletal Manifestations of Haemophilia A and BActa Orthopaedica, 1965